ArticleBMC pharmacology & toxicology2025
Multi-target antidiabetic therapy with voglibose, ubiquinone, and tempol: synergistic effects on liver and skeletal muscle in experimental type 2 diabetes.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundType 2 Diabetes Mellitus (T2DM) is a progressive metabolic disorder marked by insulin resistance and chronic hyperglycemia. Although voglibose, an alpha-glucosidase inhibitor, is used in T2DM management, its efficacy is limited, particularly when used alone. This study aimed to investigate whether combining voglibose with ubiquinone and tempol—agents known for their antioxidant, anti-inflammatory, and insulin-sensitizing properties—could enhance therapeutic outcomes.
methodsA total of 62 male Wistar Albino rats were allocated into eight experimental groups, including healthy, diabetic, and various treatment combinations. Glucose metabolism, insulin sensitivity, inflammatory markers, oxidative stress parameters, and the expression levels of GLUT4, IRS1, PIK3R1 genes, as well as histopathological alterations were systematically evaluated for over a 7-week experimental period.
resultsThe combinations of voglibose + ubiquinone and voglibose + tempol + ubiquinone significantly enhanced insulin secretion, decreased blood glucose and HbA1c levels, and mitigated inflammatory and degenerative tissue alterations, demonstrating superior efficacy compared to voglibose alone and, in some parameters, even to the voglibose + glibenclamide combination. These combinations also restored GLUT4 and PIK3R1 gene expression in muscle tissue.
conclusionThe findings support that supplementing voglibose therapy with ubiquinone and tempol enhances its antidiabetic potential and may serve as a safer and more effective strategy, particularly for patients with advanced or treatment-resistant T2DM. Further clinical research is warranted to confirm translational applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.